×

Alphatec Holdings Announces Fourth Quarter and Full Year 2014 Revenue and Financial Results

CARLSBAD, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today financial results for the fourth quarter and full year ended December 31, 2014.

  • Fourth quarter revenue of $53.6 million; 1.1% growth over 2013. 4.5% growth on a constant currency basis.
  • Fourth quarter adjusted EBITDA of $8.3 million, 15.4% of revenue; 10.3% growth over 2013.
  • Annual total revenue of $207.0 million; 1.1% growth over 2013. 2.5% growth on a constant currency basis.
  • Full year adjusted EBITDA of $30.8 million, 14.9% of revenue; 22.4% growth over 2013.

Highlights of Alphatec's Fiscal Year 2014

Progressively strengthened the quality of our business:

  • U.S. revenue of $137.1 million, representing 1.6% growth over full year 2013.
  • International revenue of $69.9 million, representing 4.4% growth in constant currency over full year 2013.
  • Revenues from international operations represent 34% of global revenues.
  • Consolidated full year revenues were impacted by $2.9 million due to the devaluation of the Japanese Yen and Euro against the U.S. dollar.
  • Adjusted EBITDA of approximately $31 million, or 15% of revenue.
  • Consolidated gross margin improved 860 basis points to 69.3% from 60.7% in 2013.
  • Successfully completed phase two of the U.S. beta launch of the Arsenal Spinal Fixation System, the Company's innovative solution to treat the most complex degenerative pathologies. Full commercial launch of Arsenal is underway.
  • Biologics growth in the U.S. of over 14% in the fourth quarter of 2014.

"2014 marked a transition year for Alphatec Spine," said Jim Corbett, President and CEO of Alphatec Spine, who joined the Company in May last year. "During the year, we substantially completed the restructuring of our French operations, settled the Orthotec litigation, strengthened our executive leadership team, and achieved record-level adjusted EBITDA."

Mr. Corbett added, "We still have work to do in order to compete more effectively in the marketplace and create greater shareholder value. We have refocused the Company on a clear strategy aligned across the organization and begun executing initiatives intended to improve the fundamental quality of our business. With the support of the Company's highly engaged team, Alphatec is committed to making strides to accelerate growth and continue to improve profitability."

Quarter Ended December 31, 2014

Consolidated net revenues for the fourth quarter of 2014 were $53.6 million, representing growth of approximately 1.1% compared to $53.1 million reported for the fourth quarter of 2013, up 4.5% on a constant currency basis due to the strengthening of the U.S. Dollar. Consolidated revenues were adversely impacted by $1.3 million in foreign currency changes against the U.S. Dollar in the fourth quarter, when compared to our third quarter 2014 exchange rates. Steep declines in the valuation of the Japanese Yen and Euro against the U.S. dollar in the fourth quarter were the primary contributors. Sequentially, consolidated net revenue for the fourth quarter was up 5.1% compared to the third quarter of 2014.

U.S. net revenues for the fourth quarter of 2014 were $35.7 million, or flat when compared to $35.7 million reported for the fourth quarter of 2013. Sequentially, U.S. revenue for the fourth quarter was 2.5% higher than the third quarter of 2014.

International net revenues for the fourth quarter of 2014 were $17.9 million, up 3.3% compared to $17.4 million for the fourth quarter of 2013, or up 13.7% on a constant currency basis.

Consolidated gross profit and gross margin for the fourth quarter of 2014 were $37.7 million and 70.3%, respectively, compared to $35.3 million and 66.4%, respectively, for the fourth quarter of 2013.

Gross margin improvement in the fourth quarter of 390 basis points over the prior year is primarily due to continued diligence at managing costs and operational efficiencies, a reduction in depreciation expense, the ending of the Cross Medical settlement amortization, as well as reductions in one time charges during the prior period, including the Company's French restructuring.

Gross profit in the fourth quarter of 2014 increased 6.9% over prior year. This improvement is due to continued diligence around managing overall costs and a reduction associated with non-recurring charges mentioned previously.

Total operating expenses for the fourth quarter of 2014 were $34.7 million, reflecting a decrease of approximately 62%. This decrease is primarily attributable to the expenses related to the Orthotec legal matter and the restructuring of the Company's French operations incurred in the fourth quarter of 2013. When operating expenses are compared with non-GAAP adjustments for the fourth quarter of 2013, total operating expenses for the fourth quarter 2014 were down by 4.8%, or $1.7 million, mainly due to expense reductions and cost savings across the organization.

GAAP net loss for the fourth quarter of 2014 was $273 thousand or ($0.00) per share basic and ($0.03) per share diluted, compared to a net loss of $60.4 million, or ($0.62) per share (basic and diluted) for the fourth quarter of 2013. Please refer to the table, "Alphatec Holdings, Inc. Reconciliation of Non-GAAP Financial Measures" that follows for more detailed information.

Adjusted EBITDA in the fourth quarter of 2014 was $8.3 million, or 15.4% of revenues, compared to $7.5 million, or 14.1% of revenues reported in the fourth quarter of 2013. Fourth quarter 2014 adjusted EBITDA represents net income excluding effects of interest and other expenses, taxes, depreciation, amortization and stock-based compensation. Please refer to the table, "Alphatec Holdings, Inc. Reconciliation of Non-GAAP Financial Measures" that follows for more detailed information.

Unrestricted cash and cash equivalents were $19.7 million at December 31, 2014, compared to $21.3 million reported at December 31, 2013. Additionally, the Company has reported $6.8 million of current and non-current restricted cash, which must be used for future payment obligations associated with the Orthotec settlement.

Year Ended December 31, 2014

Consolidated net revenues for full year 2014 were $207.0 million, representing growth of 1.1%, compared to $204.7 million reported for full year 2013, or up 2.5% on a constant currency basis. Consolidated revenues were adversely impacted by $2.9 million in foreign currency changes against the U.S. Dollar for the full year 2014, predominantly changes against the Japanese Yen and Euro.

U.S. net revenues for full year 2014 were $137.1 million, representing growth of 1.6%, compared to $135.0 million reported for full year 2013.

International net revenues for full year 2014 were $69.9 million, or relatively flat on an as reported basis compared to $69.8 million for full year 2013, or up 4.4% on a constant currency basis.

Consolidated gross profit and gross margin for full year 2014 were $143.4 million and 69.3%, respectively, compared to $124.3 million and 60.7%, respectively, for full year 2013.

Gross margin for the full year 2014 increased 860 basis points over the prior year primarily due to continued diligence at managing costs and operational efficiencies, the ending of the Cross Medical settlement amortization, as well as a reduction in one time charges during the prior period including the Company's French restructuring and discontinuation of its Puregen product.

Gross profit in the fourth quarter of 2014 increased 15.4% over prior year. The continued improvement is due to the benefits of an overall increase in sales volume, continued diligence around managing overall costs and a reduction in the cost of revenues associated with non-recurring charges mentioned previously.

Total operating expenses for full year 2014 were $141.6 million, reflecting a decrease of 28.4% compared to full year 2013. This decrease is primarily attributable to the absence of expenses related to the Orthotec legal matter and the restructuring of the Company's French operations versus the full year of 2013. When operating expenses are compared with non-GAAP adjustments for the full year of 2013, total operating expense for the full year of 2014 were down by almost 2%, or $2.3 million, mainly due to savings in general and administrative expense driven primarily by the absence of the Orthotec litigation expenses offset by increased spending in R&D in 2014 associated with development and pre-commercialization of the Arsenal Spinal Fixation System. Please refer to the tables titled, "Alphatec Holdings, Inc. Non-GAAP Condensed Consolidated Statement of Operations" that follow for more detailed information.

GAAP net loss for full year 2014 was $12.9 million or ($0.13) per share basic and ($0.16) per share diluted, compared to a net loss of $82.2 million, or ($0.85) per share (basic and diluted) for full year 2013. Net loss, when adjusted for expense items related to the Orthotec legal matter and the restructuring of the Company's French operations discussed previously, IPR&D, as well as warrants issued in connection with the Deerfield credit facility, was $9.4 million for full year 2014, or ($0.10) per share basic and diluted, compared to a non-GAAP EPS for the full year of 2013 of ($0.14) per share (basic and diluted). Please refer to the tables titled, "Alphatec Holdings, Inc. Non-GAAP Condensed Consolidated Statement of Operations" that follow for more detailed information.

Adjusted EBITDA for full year 2014 was $30.8 million, or 14.9% of revenues, compared to $25.2 million, or 12.3% of revenues reported for full year 2013. Full year 2014 adjusted EBITDA represents net income excluding effects of interest and other expenses, taxes, depreciation, amortization, stock-based compensation, IPR&D and the following items: a non-recurring expense of $4.8 million associated with the settlement of the Orthotec litigation and trial-related litigation expenses and $706 thousand of expenses related to restructuring of the Company's French operations. Please refer to the table, "Alphatec Holdings, Inc. Reconciliation of Non-GAAP Financial Measures" that follows for more detailed information.

2015 Financial Guidance

The Company anticipates full year 2015 constant currency revenue growth of approximately 4% to 7% over 2014, which represents a range of revenue in constant currency of $215 million to $222 million. Additionally, the Company expects annual adjusted EBITDA of $34 million to $37 million in 2015, representing a range of approximately 10% to 20% growth over 2014.

Conference Call

Alphatec Spine will webcast its Quarterly Update Call today at 5:00 p.m. EDT / 2:00 p.m. PDT. Jim Corbett, President and CEO of Alphatec Spine, will lead the call. During the call the Company plans to provide further details underlying its fourth quarter 2014 financial results.

To access the webcast, please log on to www.alphatecspine.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the internet, the live call may be accessed by phone by calling toll-free (877) 556-5251 (U.S. / Canada) or (720) 545-0036 (international), participant passcode number 80756901. A replay of the call will also be available on the investor relations section of Alphatec Spine's website for at least 30 days.

Non-GAAP Information

Alphatec Spine reports certain non-GAAP financial measures such as non-GAAP earnings and earnings per share, adjusted for effects of amortization and other non-recurring or expense items, such as loss on extinguishment of debt, restructuring expenses and transaction-related expenses. Adjusted EBITDA included in this press release is a non-GAAP financial measure that represents net income (loss) excluding the effects of interest, taxes, depreciation, amortization, stock-based compensation expenses, in process research and development (IPR&D) expenses and other non-recurring income or expense items, such as severance expense, litigation expenses, damages associated with ongoing litigation and transaction-related expenses. The Company believes that non-GAAP adjusted EBITDA provides investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a base-line for assessing the future earnings potential of the Company. For completeness, management uses non-GAAP adjusted EBITDA in conjunction with GAAP earnings and earnings per common share measures. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a global medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. and internationally via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward looking statements include the references to Alphatec Spine's 2015 revenue guidance and 2015 adjusted EBITDA guidance; the success of the Company's initiatives to drive global sales growth, increase margins and increase operating efficiencies. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in Alphatec Spine's pipeline; the uncertainties in the Company's ability to execute upon is strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of Alphatec Spine's products by the surgeon community, including the Arsenal Spinal Fixation System and the Company's biologics products; failure to successfully implement streamlining and lean activities to create anticipated savings; failure to obtain FDA clearance or approval or international regulatory approvals for new products, including the products discussed in this press release, or unexpected or prolonged delays in the process; continuation of favorable third party payor reimbursement for procedures performed using the Company's products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company's ability to compete with other competing products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any material litigation in which the Company is a defendant; patent infringement claims; claims related to the Company's intellectual property and the Company's ability to meet its financial obligations under its credit agreements and the Orthotec settlement agreement. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K for the year ended December 31, 2013, filed on March 20, 2014 with the Securities and Exchange Commission, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts - unaudited)
Three Months Ended Year Ended
December 31, December 31,
2014 2013 2014 2013
Revenues $ 53,627 $ 53,065 $ 206,980 $ 204,724
Cost of revenues 15,529 17,366 61,834 78,669
Amortization of acquired intangible assets 408 444 1,736 1,733
Total cost of revenues 15,937 17,810 63,570 80,402
Gross profit 37,690 35,255 143,410 124,322
Operating expenses:
Research and development 3,661 3,814 16,799 14,190
In-process research and development -- -- 527 --
Sales and marketing 20,634 21,156 77,179 76,960
General and administrative 9,705 13,931 43,381 47,949
Amortization of acquired intangible assets 717 754 2,974 3,009
Litigation settlement -- 45,982 -- 45,982
Restructuring expenses -- 5,620 706 9,665
Total operating expenses 34,717 91,257 141,566 197,755
Operating loss 2,973 (56,002) 1,844 (73,433)
Interest and other income (expense), net (3,107) (2,109) (13,639) (5,615)
Loss from continuing operations before taxes (134) (58,111) (11,795) (79,048)
Income tax provision 139 2,296 1,087 3,179
Net loss $ (273) $ (60,407) $ (12,882) $ (82,227)
Net loss per common share:
Basic net loss per share $ (0.00) $ (0.62) $ (0.13) $ (0.85)
Diluted net loss per share $ (0.03) $ (0.62) $ (0.16) $ (0.85)
Weighted average shares
Basic 98,261 96,793 97,347 96,235
Diluted 98,477 96,793 97,735 96,235
ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands - unaudited)
December 31, December 31,
2014 2013
ASSETS
Current assets:
Cash and cash equivalents $ 19,735 $ 21,345
Restricted cash 4,400 --
Accounts receivable, net 40,440 41,395
Inventories, net 41,747 41,939
Prepaid expenses and other current assets 5,466 7,694
Deferred income tax assets 1,324 1,372
Total current assets 113,112 113,745
Property and equipment, net 26,040 28,030
Goodwill 171,333 183,004
Intangibles, net 30,259 39,064
Other assets 4,179 1,787
Total assets $ 344,923 $ 365,630
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 10,130 $ 10,790
Accrued expenses 35,393 62,996
Deferred revenue 1,300 1,009
Common stock warrant liabilities 8,702 --
Current portion of long-term debt 8,076 4,924
Total current liabilities 63,601 79,719
Total long term liabilities 108,765 90,632
Redeemable preferred stock 23,603 23,603
Stockholders' equity 148,954 171,676
Total liabilities and stockholders' equity $ 344,923 $ 365,630
ALPHATEC HOLDINGS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in thousands, except per share amounts - unaudited)
Three Months Ended Year Ended
December 31, December 31,
2014 2013 2014 2013
Operating loss, as reported $ 2,973 $ (56,002) $ 1,844 $ (73,433)
Add back:
Depreciation 2,913 3,786 12,160 14,638
Amortization of intangible assets 341 1,330 1,515 6,898
Amortization of acquired intangible assets 1,125 1,197 4,710 4,741
Total EBITDA 7,352 (49,689) 20,229 (47,156)
Add back significant items:
Stock-based compensation 913 1,246 4,554 4,078
In-process research and development -- -- 527 --
Litigation settlement and trial costs -- 49,657 4,779 49,657
Restructuring and other charges -- 6,282 742 18,603
EBITDA, as adjusted for significant items $ 8,265 $ 7,496 $ 30,831 $ 25,182
Net loss, as reported $ (273) $ (60,407) $ (12,882) $ (82,227)
Add back:
In-process research and development -- -- 527 --
Amortization of acquired intangible assets 1,125 1,197 4,710 4,741
Amortization of intangible assets 341 1,330 1,515 6,898
Warrant fair value adjustment (2,870) -- (2,578) --
Litigation settlement and trial costs -- 49,657 4,779 49,657
Restructuring and other charges -- 6,282 742 18,603
Net loss, as adjusted for significant items $ (1,677) $ (1,941) $ (3,187) $ (2,328)
Net loss per common share - basic and diluted $ (0.00) $ (0.62) $ (0.13) $ (0.85)
Add back:
In-process research and development -- -- 0.01 --
Amortization of acquired intangible assets 0.01 0.01 0.05 0.05
Amortization of intangible assets 0.00 0.01 0.02 0.07
Warrant fair value adjustment (0.03) -- (0.03) --
Litigation settlement and trial costs -- 0.51 0.05 0.52
Restructuring and other charges -- 0.06 0.01 0.19
Net loss per common share - basic and diluted, as adjusted for significant items $ (0.02) $ (0.02) $ (0.03) $ (0.02)
Weighted-average shares - basic and diluted 98,261 96,793 97,347 96,235
ALPHATEC HOLDINGS, INC.
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES AND GROSS PROFIT
(in thousands, except percentages - unaudited)
Three Months Ended % Change
December 31, % Change % Change Foreign
2014 2013 As Reported Operations Currency
Revenues by geographic segment
U.S. $ 35,683 $ 35,702 -0.1% -0.1% 0.0%
International 17,944 17,363 3.3% 13.7% -10.4%
Total revenues $ 53,627 $ 53,065 1.1% 4.5% -3.4%
Gross profit by geographic segment
U.S. $ 26,358 $ 26,058
International 11,332 9,197
Total gross profit $ 37,690 $ 35,255
Gross profit margin by geographic segment
U.S. 73.9% 73.0%
International 63.2% 53.0%
Total gross profit margin 70.3% 66.4%
Year Ended % Change
December 31, % Change % Change Foreign
2014 2013 As Reported Operations Currency
Revenues by geographic segment
U.S. $ 137,060 $ 134,951 1.6% 1.6% 0.0%
International 69,920 69,773 0.2% 4.4% -4.2%
Total revenues $ 206,980 $ 204,724 1.1% 2.5% -1.4%
Gross profit by geographic segment
U.S. $ 100,568 $ 88,900
International 42,842 35,422
Total gross profit $ 143,410 $ 124,322
Gross profit margin by geographic segment
U.S. 73.4% 65.9%
International 61.3% 50.8%
Total gross profit margin 69.3% 60.7%
Footnotes:
1) The impact from foreign currency represents the percentage change in 2014 revenues due to the change in foreign exchange rates for the periods presented.
ALPHATEC HOLDINGS, INC.
NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts - unaudited)
Three Months Ended December 31, 2014
Non-GAAP
GAAP Adjustments Non-GAAP
Revenues $ 53,627 $ -- $ 53,627
Cost of revenues 15,529 -- 15,529
Amortization of acquired intangible assets 408 -- 408
Total cost of revenues 15,937 -- 15,937
Gross profit 37,690 -- 37,690
70.3% 70.3%
Operating expenses:
Research and development 3,661 -- 3,661
In-process research and development -- -- --
Sales and marketing 20,634 -- 20,634
General and administrative 9,705 -- 9,705
Amortization of acquired intangible assets 717 -- 717
Transaction related costs -- --
Litigation settlement -- -- --
Restructuring expenses -- -- --
Total operating expenses 34,717 -- 34,717
Operating loss 2,973 -- 2,973
Interest and other income (expense), net (3,107) (2,870) (a) (5,977)
Loss from continuing operations before taxes (134) (2,870) (3,003)
Income tax provision 139 -- 139
Net loss $ (273) $ (2,870) $ (3,142)
Year Ended December 31, 2014
Non-GAAP
GAAP Adjustments Non-GAAP
Revenues $ 206,980 $ -- $ 206,980
Cost of revenues 61,834 -- 61,834
Amortization of acquired intangible assets 1,736 -- 1,736
Total cost of revenues 63,570 -- 63,570
Gross profit 143,410 -- 143,410
69.3% 69.3%
Operating expenses:
Research and development 16,799 -- 16,799
In-process research and development 527 (527) (b) --
Sales and marketing 77,179 -- 77,179
General and administrative 43,381 (4,779) (c) 38,602
Amortization of acquired intangible assets 2,974 -- 2,974
Litigation settlement -- -- --
Restructuring expenses 706 (776) (d) (70.00)
Total operating expenses 141,566 (6,082) 135,484
Operating loss 1,844 6,082 7,926
Interest and other income (expense), net (13,639) (2,578) (a) (16,217)
Loss from continuing operations before taxes (11,795) 3,504 (8,290)
Income tax provision 1,087 -- 1,087
Net loss $ (12,882) $ 3,504 $ (9,377)
Notes:
(a) Consists of warrant fair value adjustment.
(b) Represents initial payments for products that are not considered technologically feasible upon acquisition.
(c) Consists of Orthotec litigation trial related costs.
(d) Employee severance and facility closing costs accrued for the restructuring of the Company's French operations.
ALPHATEC HOLDINGS, INC.
NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts - unaudited)
Three Months Ended December 31, 2013
Non-GAAP
GAAP Adjustments Non-GAAP
Revenues $ 53,065 $ -- $ 53,065
Cost of revenues 17,366 (1,131) (a) 16,235
Amortization of acquired intangible assets 444 -- 444
Total cost of revenues 17,810 (1,131) 16,679
Gross profit 35,255 1,131 36,386
66.4% 68.6%
Operating expenses:
Research and development 3,814 -- 3,814
Sales and marketing 21,156 -- 21,156
General and administrative 13,931 (3,206) (b) 10,725
Amortization of acquired intangible assets 754 -- 754
Litigation settlement 45,982 (45,982) (c) --
Restructuring expenses 5,620 (5,620) (d) --
Total operating expenses 91,257 (54,808) 36,449
Operating loss (56,002) 55,939 (63)
Interest and other income (expense), net (2,109) -- (2,109)
Loss from continuing operations before taxes (58,111) 55,939 (2,171)
Income tax provision 2,296 -- 2,296
Net loss $ (60,407) $ 55,939 $ (4,468)
Year Ended December 31, 2013
Non-GAAP
GAAP Adjustments Non-GAAP
Revenues $ 204,724 $ -- $ 204,724
Cost of revenues 78,669 (9,176) (a) (e) 69,493
Amortization of acquired intangible assets 1,733 -- 1,733
Total cost of revenues 80,402 (9,176) 71,226
Gross profit 124,322 9,176 133,498
60.7% 65.2%
Operating expenses:
Research and development 14,190 (162) (f) 14,028
Sales and marketing 76,960 -- 76,960
General and administrative 47,949 (4,168) (b) (g) 43,781
Amortization of acquired intangible assets 3,009 -- 3,009
Litigation settlement 45,982 (45,982) (c) --
Restructuring expenses 9,665 (9,665) (d) --
Total operating expenses 197,755 (59,977) 137,778
Operating loss (73,433) 69,153 (4,280)
Interest and other income (expense), net (5,615) -- (5,615)
Loss from continuing operations before taxes (79,047) 69,153 (9,894)
Income tax provision 3,179 -- 3,179
Net loss $ (82,227) $ 69,153 $ (13,074)
Notes:
(a) Record inventory and instrument net book value adjustment and other costs of $1.1 million and $5.6 million for the three months and year ended December 31, 2013, respectively, related to the restructuring of the Company's French operations.
(b) Amount consists of Orthotec litigation trial related costs of $3.7 million, partially offset by Phygen related escrow claim.
(c) Litigation settlement related to the Orthotec litigation.
(d) Employee severance and facility closing costs accrued for the restructuring of the Company's French operations.
(e) Includes write-off of inventory and intangibles of $3.5 million related to the Company's Puregen product.
(f) Expense related to research and development technology.
(g) Amount includes Phygen related acquisition costs of $0.4 million.

CONTACT: Investor/Media Contact: Christine Zedelmayer Investor Relations Alphatec Spine, Inc. (760) 494-6610 czedelmayer@alphatecspine.com

Source:Alphatec Holdings, Inc.